Cartesian Therapeutics, Inc. (RNAC) Tops Q2 EPS by 144c

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) reported Q2 EPS of $0.54, $1.44 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $33.44 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Cartesian Therapeutics, Inc. (RNAC) click here.

You May Also Be Interested In

• Brinker International (EAT) Misses Q4 EPS by 2c ; Offers Guidance
• PagSeguro Digital Ltd. (PAGS) Misses Q2 EPS by 2c
• Global-e Online (GLBE) Tops Q2 EPS by 16c ; Offers Guidance